This article is more than 5 years old. Information may no longer be current.
Miraca adds Stelara to IBD drug monitoring service
Click Here to Manage Email Alerts
Miraca Life Sciences has expanded its InformTx therapeutic drug monitoring service for inflammatory bowel disease to include Stelara, according to a press release.
Stelara (ustekinumab, Janssen) is the first biologic for Crohn’s disease that targets interleukin (IL)-12 and IL-23 cytokines. It was recently approved for Crohn’s disease by the FDA in September.
This adds to the company’s therapeutic drug monitoring (TDM) services for Remicade (infliximab, Janssen), Humira (adalimumab, AbbVie), Cimzia (certolizumab pegol, UCB) and Entyvio (vedolizumab, Takeda).
TDM is becoming an increasingly important tool for maximizing drug efficacy, minimizing toxicity and maintaining remission, as accumulating data show anti-TNF drug and antidrug antibody serum concentrations are associated with treatment response in IBD.
InformTx TDM uses laboratory-validated ELISA technology, and the report provides quantitative test results, historical test result data, and guidance from current peer-reviewed scientific literature. Results are reported within 5 days, according to the press release.
“Increasing the number of drugs which we can test with our InformTx therapeutic drug monitoring allows us to provide critical information to help guide therapy for even more gastroenterologists and their patients,” Richard Lash, MD, chief medical officer and executive vice president of operations for Miraca Life Sciences, said in the press release. “We plan to add more biologics to our InformTx testing service over time.”
Disclosures: Lash is employed by Miraca.